Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Prn1008
2. 1575596-29-0
3. Prn-1008
4. Rilzabrutinib, (e)-
5. 5g1we425bi
6. Prn1008, (e)-
7. (e)-2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
8. Prn-1008, (e)-
9. (r,e)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile
10. (2e)-2-{(3r)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl}-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
11. 1575591-66-0
12. 2-((3r)-2-(4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo(3,4-d)pyrimidin-1-yl)piperdine-1-carbonyl)-4-methyl-4(4-(oxetan-3-yl)piperazin-1-yl-(e)-pent-2-enenitrile
13. Rilzabrutinib [inn]
14. Rilzabrutinib [usan]
15. Unii-nwn58m4f5t
16. Rilzabrutinib (usan/inn)
17. Nwn58m4f5t
18. Unii-5g1we425bi
19. Gtpl9993
20. Chembl3702854
21. Schembl15506003
22. Bdbm143212
23. (r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile
24. Ex-a4524
25. Prn 1008
26. Bdbm50557485
27. Nsc812901
28. Who 10966
29. Nsc-812901
30. Example 31 [wo2014039899]
31. Ac-36557
32. Hy-112166
33. Cs-0043590
34. D11873
35. D87222
36. Us8940744, 31
37. Q50825085
38. (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile
39. 1-piperidinepropanenitrile, 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2-methyl-2-(4-(3-oxetanyl)-1-piperazinyl)propylidene)-beta-oxo-, (alphae/z,3r)-
40. 1-piperidinepropanenitrile, 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1hpyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2-methyl-2-(4-(3-oxetanyl)-1-piperazinyl)propylidene)-beta-oxo-, (3r)-
| Molecular Weight | 665.8 g/mol |
|---|---|
| Molecular Formula | C36H40FN9O3 |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 8 |
| Exact Mass | 665.32381433 g/mol |
| Monoisotopic Mass | 665.32381433 g/mol |
| Topological Polar Surface Area | 139 Ų |
| Heavy Atom Count | 49 |
| Formal Charge | 0 |
| Complexity | 1230 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of immune thrombocytopenia

NDC Package Code : 54236-080
Start Marketing Date : 2020-04-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
42
PharmaCompass offers a list of Rilzabrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rilzabrutinib manufacturer or Rilzabrutinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rilzabrutinib manufacturer or Rilzabrutinib supplier.
PharmaCompass also assists you with knowing the Rilzabrutinib API Price utilized in the formulation of products. Rilzabrutinib API Price is not always fixed or binding as the Rilzabrutinib Price is obtained through a variety of data sources. The Rilzabrutinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 1575591-66-0 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 1575591-66-0, including repackagers and relabelers. The FDA regulates 1575591-66-0 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 1575591-66-0 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 1575591-66-0 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 1575591-66-0 supplier is an individual or a company that provides 1575591-66-0 active pharmaceutical ingredient (API) or 1575591-66-0 finished formulations upon request. The 1575591-66-0 suppliers may include 1575591-66-0 API manufacturers, exporters, distributors and traders.
click here to find a list of 1575591-66-0 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 1575591-66-0 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 1575591-66-0 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 1575591-66-0 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 1575591-66-0 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 1575591-66-0 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 1575591-66-0 suppliers with NDC on PharmaCompass.
1575591-66-0 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 1575591-66-0 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 1575591-66-0 GMP manufacturer or 1575591-66-0 GMP API supplier for your needs.
A 1575591-66-0 CoA (Certificate of Analysis) is a formal document that attests to 1575591-66-0's compliance with 1575591-66-0 specifications and serves as a tool for batch-level quality control.
1575591-66-0 CoA mostly includes findings from lab analyses of a specific batch. For each 1575591-66-0 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
1575591-66-0 may be tested according to a variety of international standards, such as European Pharmacopoeia (1575591-66-0 EP), 1575591-66-0 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (1575591-66-0 USP).